anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: chemistry of peptides. SUBSTANCE: product: peptides of the general formula: Trp-X-Gly-Gly-Asp-R where X - residue of hydroxyl-containing amino acid of L- or D-configuration; R - peptide Ala-Ser-Gly-Glu or Ala-Ser-Gly, or Ala-Ser or Ala, and their pharmaceutically acceptable salts also. Synthesis of peptides is carried out by the successive peptide chain splicing using tert.-butylhydroxycarbonyl scheme of solid-phase peptide synthesis. Synthesis is carried out at automatic regime in peptide synthesizer. Synthesized peptides are used in medicine since they show antistress, anticonvulsant and neuroprotective effect. EFFECT: improved method of synthesis, enhanced effectiveness of peptides. 7 tbl
A poliomyelitis virus vaccine for immunizing primates is prepared by modifying poliomyelitis virus by serial passage in suckling rodents until it has become adapted to grow in chick embryos, inoculating chick embryos with said modified poliomyelitis virus and after a period of incubation in said chick embryos, harvesting the embryonic tissue and recovering the poliomyelitis virus therefrom; continuing the steps of inoculation, incubation and harvesting until the virus is modified so that it may be administered to primates by oral ingestion without causing illness but with the production of protective antibodies and then preparing the poliomyelitis vaccine from the harvested embryonic tissue of the final passage.  A poliomyelitis virus which will propagate in the central nervous tissue of rodents is obtained (a) from the American Type Culture Collection, or (b) by serial passage of a specified strain through mice and then hamsters of 6 to 8 weeks.  An aqueous suspension of the modified virus is inoculated intracerebrally into suckling rodents, preferably of 1 to 12 days old, and just prior to the time when they show evidence of paralysis, i.e. when the virus titre is at a maximum, the rodents are sacrificed and a suspension, usually isotonic, is made of their central nervous tissue.  This suspension is inoculated intracerebrally into other suckling rodents and serial passages through suckling rodents are made until the LD50 mouse titre of the virus suspension is at least 10-5.  The virus is then propagated serally in chick embryos, especially 7-day-old chick embryos with incubation at 37 DEG  C. for 7 days, until the virus has been modified sufficiently to be safely used on humans, as shown by tests with monkeys.  A live virus vaccine may be prepared by grinding the chick embryonic tissue in isotonic saline solution or Ringer's solution and centrifuging to remove gross tissue, if desired.  It may be taken orally alone or in admixture with food such as milk or chocolate.  A killed poliomyelitis virus vaccine is obtained by treating the live virus vaccine with an inactivating agent such as phenol, formalin or ethylene oxide.  A diagnostic antigen is obtained by drying the killed virus vaccine, extracting the dried material with a fat solvent and adding saline solution to the extracted product.
A method for the surgical treatment of the backbone injuries combined with hemangioma of the bodies of vertebrae comprises the use of the transpedicular constructions or the puncture vertebroplasty. The stabilization of the backbone with the transpedicular construction is combined with correction of the deformities. The vertebroplasty of the vertebra with hemangioma is provided from the same approach. The soft tissues are cut by the linear midline incision over the site required the surgical correction. The lumbodorsal fascia is cut on both sides. The posterior parts of the vertebrae requiring fixation are skeletized to the articular processes. The screws of the fixation device are inserted into the body of vertebra transpedicularly from both sides according to the conventional technique. The location and the number of the fixed backbone segments depend on the degree of vertebral injury and instability of the segment. The screws are fixed onto the reposition rods. The rods are connected rigidly with the transpedicular screws generating the whole rigid construction. The zygapophysial joints are localized from the major approach, and the needle with mandrin is inserted into the body of vertebra through the pedicle from the wound or transcutaneously. The standard cement for vertebroplasty is injected, and the wound is sutured layer-by-layer with active drainages left.
BACKGROUND: Brain ischemia-reperfusion injury is a complex process, and neuroinflammation is an important secondary contributing pathological event. Neutrophils play major roles in ischemic neuroinflammation. Once activated, neutrophils express formyl peptide receptors (FPRs), which are special receptors of a class of chemoattractants and may be potential targets to regulate the activity of neutrophils and control cerebral ischemic injury. This study was aimed to explore the ameliorating effect of Cyclosporin H (CsH), a potent FPR antagonist, on brain ischemic injury by inhibiting the activation and migration of neutrophils, and improving cerebral blood flow.
METHODS: We employed a middle cerebral artery occlusion (MCAO) Model on rats and performed behavioral, morphological, and microPET imaging assays to investigate the potential restoring efficacy of CsH on cerebral ischemic damages. Peptide N-cinnamoyl-F-(D)L-F-(D)L-F (cFLFLF), an antagonist to the neutrophil FPR with a high binding affinity, was used for imaging neutrophil distribution.
RESULTS: We found that CsH had similar effect with edaravone on improving the neurobehavioral deficient symptoms after cerebral ischemia-reperfusion, and treatment with CsH also alleviated ischemic cerebral infarction. Compared with the MCAO Model group, [18F]FDG uptake ratios of the CsH and edaravone treatment groups were significantly higher. The CsH-treated groups also showed significant increases in [18F]FDG uptake at 144 h when compared with that of 24 h. This result indicates that like edaravone, treatment with both doses of CsH promoted the recovery of blood supply after cerebral ischemic event. Moreover, MCAO-induced cerebral ischemia significantly increased the radiouptake of [68Ga]Ga-cFLFLF at 72 h after ischemia-reperfusion operation. Compared with MCAO Model group, radiouptake values of [68Ga]-cFLFLF in both doses of CsH and edaravone groups were all decreased significantly. These results showed that both doses of CsH resulted in a similar therapeutic effect with edaravone on inhibiting neutrophil infiltration in cerebral infarction.
CONCLUSION: Potent FPR antagonist CsH is promisingly beneficial in attenuating neuroinflammation and improving neurobehavioral function against cerebral infarction. Therefore, FPR may become a novel target for regulating neuroinflammation and improving prognosis for ischemic cerebrovascular disorders.
Autogenous arteriovenous fistula (AVF) is the preferred dialysis access for receiving hemodialysis treatment in end-stage renal disease patients. After AVF is established, vascular remodeling occurs in order to adapt to hemodynamic changes. Uremia toxins, surgical injury, blood flow changes and other factors can induce inflammatory response, immune microenvironment changes, and play an important role in the maintenance of AVF vascular remodeling. This process involves the infiltration of pro-inflammatory and anti-inflammatory immune cells and the secretion of cytokines. Pro-inflammatory and anti-inflammatory immune cells include neutrophil (NEUT), dendritic cell (DC), T lymphocyte, macrophage (Mφ), etc. This article reviews the latest research progress and focuses on the role of immune microenvironment changes in vascular remodeling of AVF, in order to provide a new theoretical basis for the prevention and treatment of AVF failure.
Prostate brachytherapy is a popular treatment for clinically localized prostate cancer. In properly selected patients, it is highly effective with biochemical (PSA) disease free survival rates of 85-95% at 5-10 years. However, the technique is currently limited by the inability to localize the cancer within the prostate. The multifocal nature of prostate cancer is well established. Because of the inability to know where within the prostate the cancer is located, radiation must be delivered throughout the gland. Although this blind approach leads to good results, it is clear that there are regions of the prostate and surrounding tissue that are overexposed to radiation while others are underexposed relative to their true need based on their tumor burden and their proximity to the tumor areas. Multiple studies have shown significant correlation between MRI abnormalities and radical prostatectomy specimens for determining size and location of cancer foci. MRI images have already begun to be incorporated into diagnostic and therapeutic procedures for prostate cancer on an experimental basis by other investigators. The images have been fused with real time TRUS to successfully perform targeted biopsies. In this study, we propose to use MRI images in the pre-treatment planning process to identify the tumors within the prostate prior to the brachytherapy and use these images to direct the dosimetry planning. The primary goal of this study is to decrease the chronic toxicities as assessed by the Common Toxicity Criteria Version 4.0 by decreasing the integral dose to the regions of the prostate which do not have tumor. A secondary goal is to increase the dose to the tumor(s) and demonstrate this ability while maintaining the urethral and other normal tissue doses. We also wish to perform dosimetric comparisons of the normal tissues and the tumor(s) when this technique is used compared to what would have been done if the patient had received a traditional implant. Finally, we propose to perform a prostate MRI followed by a biopsy to evaluate for persistent/recurrent disease at 2 years after treatment.
It is known that the presence of orthodontic brackets predisposes for a change in both the quantity and quality of the biofilm, due to the challenge of brushing adequately. The sites are difficult to access with a toothbrush and periodontal curette, worsening inflammation. In addition, gingival growth is frequently associated with poor hygiene. The hypothesis to be tested in this study is whether photodynamic therapy (PDT) could favor the decontamination of these areas, as the photosensitizer and light are capable of reaching areas that these instruments have difficulty accessing. In other words, the objective of this study is to evaluate the impact of PDT as an adjuvant treatment to scaling, considering clinical and immunoregulatory parameters in patients with gingivitis with the predisposing factor of the use of a fixed orthodontic appliance. A randomized, controlled, double-blind, split-mouth clinical study will include 17 patients, both genders, having used the fixed appliance for more than 12 months, with gingivitis present. Patients will have their mouth divided into two groups: Control group (n = 17) - Scaling and Root Planing (SRP) + PDT placebo and Experimental group (n = 17) - SRP + PDT. In G2 methylene blue 0.005%, λ = 660nm, 9J (joule) per inflamed site, irradiance = 3.5W/ cm, radiant exposure = 318J/ cm2. In G1 and G2 the scaling will be performed with the aid of the ultrasound. All participants will receive oral hygiene guidance (OHG) after to the end of the study. The clinical periodontal data to be analyzed: plaque index (PI), gingival index (GI) and probing depth (PD) and clinical level of insertion (CLI) by means of a periodontal probe. Crevicular fluid will be collected (from 8 pre-determined sites) for analysis of the IL-6, IL-1β, IL-8, TNF-α and IL-10 cyttokines, using the ELISA method. All analysis will be realized using the baseline (T0) and (T1) 30 days after treatment. If sample distribution is normal, the Student T-test will be used to compare the measurement of continuous and dependent variables. If it is not normal, the Mann-Whitney test will be used. The data will be presented in terms of ± PD and the value of p will be defined as 0.05.
The present invention provides a renal health-care capsule with Taiwan green propolis extract, including a capsule body and the content. The capsule body surrounds an accommodating space with two closed ends located at opposite ends of the capsule body. The accommodating space is isolated from the outside. The content arranged in the accommodating space contains Taiwan green propolis extract. Thus Taiwan green propolis capsule is easy to store and carry. With the invention, propolis extract is convenient for daily consumption to achieve the purpose of renal health care: improving renal function, parenchymal fibrosis and progression of chronic kidney disease.
Quorum Sensing Inhibitor from the Bark of Pithecellobium dulce (Kamatsile) and the process of making thereof. The present invention relates to a composition for anti-pathogenic drugs more particularly to quorum sensing inhibitor syrup from the semi-purified tannins of Pithecellobium dulce (kamatsile) bark. The increased prevalence of antibiotic-resistant bacteria due to the extensive use of antibiotics has rendered the current antimicrobial agents inefficient to control several bacterial diseases. Many opportunistic pathogenic bacteria depend on QS systems to coordinate their virulence expression. Thus, interference with QS has been regarded as the novel way to control bacterial infections. One of the measures to combat this problem is to have continuous investigations into new, safe and effective alternative agents to substitute the present less effective ones. Plants have been traditionally proven to be a rich source of novel drug compounds and its herbal mixtures have made a large contribution to human health and well being. Thus, it becomes necessary to analyze the vast untapped potential of the medicinal plants in combating the antibiotic resistant organisms.
BACKGROUND: Treatment of anorexia nervosa (AN) sometimes requires hospitalisation, which is often lengthy, with little ability to predict individual trajectory. Depicting specific profiles of treatment response and their clinical predictors could be beneficial to tailor inpatient management. The aim of this research was to identify clusters of weight recovery during inpatient treatment, and their clinical predictors.
METHODS: A sample of 181 inpatients who completed a treatment programme for AN was included in a retrospective study. A latent class mixed model approach was used to identify distinct weight-gain trajectories. Clinical variables were introduced in a multinomial logistic regression model as predictors of the different classes.
RESULTS: A four-class quadratic model was retained, able to correctly classify 63.7% of the cohort. It encompassed a late-rising, flattening, moderate trajectory of body mass index (BMI) increase (class 1), a late-rising, steady, high trajectory (class 2), an early-rising, flattening, high trajectory (class 3) and an early-rising, steady, high trajectory (class 4). Significant predictors of belonging to a class were baseline BMI (all classes), illness duration (class 2), and benzodiazepine prescription (class 3).
CONCLUSION: Predicting different kinetics of weight recovery based on routinely collected clinical indicators could improve clinician awareness and patient engagement by enabling shared expectations of treatment response.
Despite the decreased rates in inflammatory bowel disease (IBD) colectomies due to high advances in therapeutic options, a significant number of patients still require proctocolectomy with ileal pouch-anal anastomosis (IPPA) for ulcerative colitis (UC). Pouchitis is the most common complication in these patients, where up to 60% develop one episode of pouchitis in the first two years after UC surgery with IPAA with severe negative impact on their quality of life. Acute cases usually respond well to antibiotics, but 15% of patients will still develop a refractory disease that requires the initiation of advanced immunosuppressive therapies. For chronic idiopathic pouchitis, current recommendations suggest using the same therapeutic options as for IBD in terms of biologics and small molecules. However, the available data are limited regarding the effectiveness of different biologics or small molecules for the management of this condition, and all evidences arise from case series and small studies. Vedolizumab is the only biologic agent that has received approval for the treatment of adult patients with moderately to severely active chronic refractory pouchitis. Despite the fact that IBD treatment is rapidly evolving with the development of novel molecules, the presence of pouchitis represents an exclusion criterion in these trials. Recommendations for the approach of these conditions range from low to very low certainty of evidence, resulting from small randomized controlled trials and case series studies. The current review focuses on the therapeutic management of idiopathic pouchitis.
This is a prospective, randomize, double-blinded study in preterm infants born between 28-34 weeks gestation admitted to the NICU at the University of Kansas Hospital. After obtaining informed consent, babies will be randomized to either liquid or powdered HMF using opaque, sealed envelopes with preassigned randomization. The feeding protocol as established in the KU NICU will be followed, beginning with initiation of trophic feeds, and advancement of enteral feeds depending on the gestational age and preceding illnesses. Once infants reach 80ml/kg/day of enteral feeds, human milk will be fortified to 22 kilocalories by adding either liquid or powdered fortifier. The beginning of the study(Study day 1) will be defined as reaching and tolerating 100ml/kg/day of 24 kilocalorie human milk fortified with either liquid or powdered fortifier. Enteral feeds will be advanced per unit protocol until they reach 150-160ml/kg/day and 110-120 kcal/kg/day. the volume of feeds will be adjusted based on the documented weight to provide energy and protein requirements as recommended by the ESPGHAN guidelines. Babies will be followed up until the time of NICU discharge.
In Study 1 [see Clinical Studies (14)] and in long-term studies, 85% of patients treated with DAYBUE experienced diarrhea. In those treated with DAYBUE, 49% either had persistent diarrhea or recurrence after resolution despite dose interruptions, reductions, or concomitant antidiarrheal therapy. Diarrhea severity was of mild or moderate severity in 96% of cases. In Study 1, antidiarrheal medication was used in 51% of patients treated with DAYBUE.

Advise patients to stop laxatives before starting DAYBUE. If diarrhea occurs, patients should notify their healthcare provider, consider starting antidiarrheal treatment, and monitor hydration status and increase oral fluids, if needed. Interrupt, reduce dose, or discontinue DAYBUE if severe diarrhea occurs or if dehydration is suspected [see Dosage and Administration (2.4)].
Maintenance of genome integrity is instrumental in preventing cancer. In addition to DNA repair pathways that prevent damage to DNA, damage tolerance pathways allow for the survival of cells that encounter DNA damage during replication. The Rad6/18 pathway is instrumental in this process, mediating damage bypass by ubiquitination of proliferating cell nuclear antigen. Previous studies have shown different roles of Rad18 in vivo and in tumorigenesis. Here, we show that B cells induce Rad18 expression upon proliferation induction. We have therefore analysed the role of Rad18 in B cell activation as well as in B cell lymphomagenesis mediated by an Eµ-Myc transgene. We find no activation defects or survival differences between Rad18 WT mice and two different models of Rad18 deficient tumour mice. Also, tumour subtypes do not differ between the mouse models. Accordingly, functions of Rad18 in B cell activation and tumorigenesis may be compensated for by other pathways in B cells.
PURPOSE:To obtain a nutrient-supplying agent for mammalians including men, little in side effects, activating the function of cells to maintain the homeostasis of a body and maintain the health, and having a strong potency for the prevention of degenerative diseases and senile diseases. CONSTITUTION:This nutrient-supplying agent contains a mineral mixture having a mineral composition ratio similar to that of the primitive sea, amino acids, vitamins, a substance (e.g. polyphenol or ascorbic acid) having a scavenging action and/or an antioxidizing ability, a phenol compound (e.g. guaiacol, phenol), flavonoid, and a saccharified compound such as saccharified flavonoid. The mineral mixture has preferably a Na:K:Mg:Ca mineral composition ratio of 100:80-130:13-35:8-20 (%), and is preferably obtained the extract of Asparagus linearis. The nutrient-supplying agent is administered at a dose of 2-400mg/kg/ day in the case of the daily use as a health-assisting agent and a nutritive agent and at a dose of 100-500ml/day as a 0.2-10% solution in the case of a drinking agent.
The effects of beclomethasone dipropionate on hypothalamic-pituitary-adrenal (HPA) function have been evaluated in adult volunteers by other routes of administration. Studies with beclomethasone dipropionate by the intranasal route may demonstrate that there is more or that there is less absorption by this route of administration. There was no suppression of early morning plasma cortisol concentrations when beclomethasone dipropionate was administered in a dose of 1,000 mcg/day for 1 month as an oral aerosol or for 3 days by intramuscular injection. However, partial suppression of plasma cortisol concentrations was observed when beclomethasone dipropionate was administered in doses of 2,000 mcg/day either by oral aerosol or intramuscular injection. Immediate suppression of plasma cortisol concentrations was observed after single doses of 4,000 mcg of beclomethasone dipropionate. Suppression of HPA function (reduction of early morning plasma cortisol levels) has been reported in adult patients who received 1,600-mcg daily doses of oral beclomethasone dipropionate for 1 month. In clinical studies using beclomethasone dipropionate aerosol intranasally, there was no evidence of adrenal insufficiency. The effect of BECONASE AQ Nasal Spray on HPA function was not evaluated but would not be expected to differ from intranasal beclomethasone dipropionate aerosol.

In 1 study in children with asthma, the administration of inhaled beclomethasone at recommended daily doses for at least 1 year was associated with a reduction in nocturnal cortisol secretion. The clinical significance of this finding is not clear. It reinforces other evidence, however, that topical beclomethasone may be absorbed in amounts that can have systemic effects and that physicians should be alert for evidence of systemic effects, especially in chronically treated patients (see PRECAUTIONS).
2.1. Difficulties may arise when certain amino acids are to be provided in dissolved form in solutions for infusion or in nutrient media, since the amino acids are either sparingly soluble or unstable in solution. The latter applies, in particular, to dipeptides. The novel dipeptide derivatives will have to be readily soluble and readily bioavailable and stable under sterilisation conditions. 2.2. The novel N-acyl-dipeptides are those of the formula  R<2>-NH-CHR<1>-CO-AS in which AS represents a natural amino acid which is sparingly soluble or unstable in solution, R<1> represents a radical of a natural amino acid, and R<2> represents an acyl radical having 1 to 6 carbon atoms. 2.3. Source of C-terminal amino acids in mixtures or solutions for enteral or parenteral (artificial and dietetic) nutrition or in nutrient media for cell cultures.